Linaclotide in Pediatric IBS-C—Evidence, Indications, and Practical Use

An expert reviews the pediatric IBS-C label expansion for linaclotide, discusses how it addresses historical evidence gaps, and outlines practical considerations for patient selection, counseling, and monitoring.

The pediatric IBS-C label expansion for linaclotide marks a meaningful advance in the treatment of disorders of gut–brain interaction in children. Julie Khlevner, MD, explains that pediatric gastroenterologists have historically relied on a mixture of lifestyle modification, laxatives, dietary interventions, behavioral therapies, and off-label medications extrapolated from adult data. While many patients improve with these measures, a substantial subgroup continues to experience abdominal pain, bloating, and constipation-related symptoms despite optimized conventional therapy. Linaclotide’s pediatric data help fill a longstanding gap by providing an FDA-approved, evidence-based pharmacologic option specifically evaluated in children with IBS-C.

Khlevner notes that pediatric patients with IBS-C often present with a broad symptom complex driven by abdominal pain and visceral hypersensitivity, even when stool frequency is partially addressed. She points out that over-the-counter osmotic laxatives may normalize stool consistency and frequency but frequently fail to adequately treat pain and global IBS symptom burden. Having pediatric-specific efficacy and safety data for linaclotide enables clinicians to counsel families more precisely about dosing, expected response, adverse effects, and monitoring, while supporting more informed shared decision-making among families who may otherwise be hesitant about off-label regimens.

From a practical standpoint, Khlevner stresses that clinicians should confirm current age indications and labeled uses for linaclotide and integrate its use within evidence-based algorithms, including the recently published ESPGHAN and NASPGHAN guidelines for functional constipation, IBS, and functional abdominal pain disorders. She recommends that treatment decisions balance efficacy, safety, tolerability, availability, and feasibility in each case and that responses to any initiated therapy be assessed at defined intervals. This approach is intended to avoid prolonged reliance on ineffective regimens and to ensure that children with persistent functional constipation or IBS-C symptoms can transition efficiently to alternative or adjunct therapies supported by robust pediatric data.